Sign In
Buy ACIU
$2.50
+0.100 (+4.17%)
At Close: Jun 22, 2026
Why Is AC Immune (ACIU) Stock Up 45% Today?
08:13am, Monday, 13'th May 2024
AC Immune (NASDAQ: ACIU ) stock is heading higher on Monday alongside the clinical-stage biopharmaceutical company's earnings report for the first quarter of 2024. Included in that earnings report is
AC Immune Reports First Quarter 2024 Financial Results and Provides a Corporate Update
06:05am, Monday, 13'th May 2024
AC Immune Reports First Quarter 2024 Financial Results and Provides a Corporate Update Landmark deal announced with Takeda for ACI-24.060 with $100 million upfront and total potential payments for opt
OSAKA, Japan & CAMBRIDGE, Mass & LAUSANNE, Switzerland--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) and AC Immune SA (NASDAQ: ACIU) today announced an exclusive, worldwide option and license agreement
AC Immune Reports Full Year 2023 Financial Results and Provides a Corporate Update
07:00am, Thursday, 14'th Mar 2024
AC Immune Reports Full Year 2023 Financial Results and Provides a Corporate Update ACI-24.060 ABATE Phase 2 trial to report Abeta-PET imaging results in Q2 and H2 ACI-7104.056 VacSYn Phase 2 trial in
AC Immune Announces Upcoming Presentations at AD/PD™ 2024
07:00am, Thursday, 22'nd Feb 2024
AC Immune Announces Upcoming Presentations at AD/PD™ 2024 Multiple presentations at the International Conference on Alzheimer's and Parkinson's Diseases (AD/PD™ 2024) Andrea Pfeifer, Ph.D., CEO to
Down -35.7% in 4 Weeks, Here's Why AC Immune (ACIU) Looks Ripe for a Turnaround
10:37am, Tuesday, 30'th Jan 2024
The heavy selling pressure might have exhausted for AC Immune (ACIU) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts
AC Immune to Regain Global Rights to Crenezumab and Semorinemab
07:00am, Monday, 22'nd Jan 2024
AC Immune to Regain Global Rights to Crenezumab and Semorinemab Company's strategy is focused on advancing the Phase 2 development of its three active immunotherapies Active immunotherapy now consider
AC Immune (ACIU) is a Great Momentum Stock: Should You Buy?
01:01pm, Thursday, 18'th Jan 2024
Does AC Immune (ACIU) have what it takes to be a top stock pick for momentum investors? Let's find out.
5 Small-Cap Stocks to Play the January Effect
11:17am, Monday, 08'th Jan 2024
Anavex Life Sciences (AVXL), Peakstone Realty Trust (PKST), AC Immune (ACIU), Getaround (GETR) and Akoya Biosciences (AKYA) could be solid picks to play the January Effect.
AC Immune (ACIU) Upgraded to Buy: Here's Why
01:32pm, Wednesday, 03'rd Jan 2024
AC Immune (ACIU) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
AC Immune Progress Update on Phase 2 Active Immunotherapy Clinical Pipeline for Alzheimer's and Parkinson diseases
08:10am, Wednesday, 03'rd Jan 2024
AC Immune Progress Update on Phase 2 Active Immunotherapy Clinical Pipeline for Alzheimer's and Parkinson diseases
AC Immune: Initial AD Findings Bring About Two Upcoming Catalysts
06:25pm, Monday, 18'th Dec 2023
Additional interim immunogenicity data using ACI-24.060 from the phase 1b/2 study, targeting Alzheimer's Disease patients, expected before end of 2023. 6-month amyloid plaque reduction data, from phas
AC Immune Announces Pricing of Underwritten Offering of Common Shares
07:56am, Friday, 15'th Dec 2023
AC Immune Announces Pricing of Underwritten Offering of Common Shares Lausanne, Switzerland, December 15, 2023 – AC Immune SA (Nasdaq: ACIU) (the “Company” or “AC Immune”), a clinical-stage
AC Immune's Targeted Anti-pTau Active Immunotherapy for Alzheimer's Disease Advances into Phase 2b Trial
07:22am, Friday, 15'th Dec 2023
AC Immune's Targeted Anti-pTau Active Immunotherapy for Alzheimer's Disease Advances into Phase 2b Trial Potentially registration-enabling Phase 2b study (ReTain) will evaluate the effect of ACI-35.03
Alzheimer's Disease Space Evolves in 2023: Stocks in Focus
10:32am, Monday, 11'th Dec 2023
The approval of the breakthrough treatment Leqembi for Alzheimer's Disease has put this space in the spotlight. Companies like ACIU, VAXX and PRTA are in focus, given their experimental vaccines.
